Enhancing Radiation for Treatment of Cancer

Summary

Technology Description

This licensing and collaborative research opportunity relates to a synergistic treatment strategy for enhancing the therapeutic efficacy of radiotherapy (RT) via nMOF-mediated drug delivery and RT enhancement. nMOF containing the high-Z element Hf and the ligand 1,4-dicarboxybenzene (Hf-BDC) was synthesized and loaded with two DNA damage repair (DDR) inhibitor drugs, talazoparib and buparlisib (TB@Hf-BDC-PEG). TB@Hf-BDC-PEG augmented RT by increasing reactive oxygen species generation and thus DNA damage of which repair was inhibited thereafter. Synergistic enhancement was demonstrated in vivo where the combination of concurrent radiation with intravenous TB@Hf-BDC-PEG administration resulted in improved tumor control and increased apoptosis. Importantly, no apparent toxicity was observed with nMOF treatment, supporting its potential as an attractive candidate over traditional nanomaterials. Polysaccharide coated second generation materials exhibit enhanced uptake in irradiated cells.

Features & Benefits

  • Enhanced radiotherapy efficacy
  • Drug loadable chemoradiotherapy platform
  • Second generation materials show enhanced uptake in irradiated cells

Applications

  • Multimodal cancer radiotherapy

Background of Invention

Due to their complementary activity, the use of DDR inhibitors during RT has yielded promising results. Unfortunately, this approach is often hindered by toxicity and poor in vivo stability of the DDR inhibitors. Nanoscale metal–organic frameworks (nMOFs) represent an emerging class of crystalline materials which exhibit advantageous properties over traditional nanomaterials and demonstrate great potential in oncology.

Status

Patent Pending (U.S. provisional patent application)

   

nMOFs coated with fucoidan show enhanced uptake in irradiated cancer cells (left) and
enhanced IR 
toxicity (right). [Radiation dose: 2 GyCell Line: CT26, murine colorectal]

Patent Information:
Tech ID:
OSU-19-76
Category(s):
Therapeutics
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Conroy Sun
Allison DuRoss
Megan Neufeld
Keywords:
Cancer
Radiation
Radiotherapy
© 2020. All Rights Reserved. Powered by Inteum